Oregon Health and Science University, Layton Aging and Alzheimer's Disease Center
Portland, Oregon, 97239, United States
NCT Number: NCT04627662
The purpose of this study is to test a revised psychoeducational intervention to help Care Partners for family members with dementia understand and reduce the distressing behaviors that come with progressive dementia. Tele-STELLA (Support via TEchnology: Living and Learning with Advancing Alzheimer's disease and related dementias) is a multicomponent videoconference-based intervention designed to facilitate effective management of behavioral and psychological symptoms common to the later stages of dementia. In the Tele-STELLA intervention, professionals ("Guides") meet with family members ("Care Partners") who care for persons with dementia. Working together, the Care Partners and Guides identify strategies to address upsetting behaviors. The goal of this intervention is to reduce upsetting behaviors and, thus, Care Partner burden.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Portland, Oregon, 97239, United States
Providing care for a family member with Alzheimer's disease and related dementias (ADRD, aka, "dementia") is both rewarding and risky. Care Partners exposed to chronic stress, often over years, are susceptible to physical and psychological ailments. Effective interventions that reduce Care Partner burden and health risks are available, but various factors impede participation, including distance, cost, behavioral symptoms of dementia, stigma and social anxiety. Recognizing the need to reduce barriers to access, scientists have turned to Internet-based interventions. Recent research indicates that multi-component, technology-facilitated interventions which allow Care Partner engagement with health professionals are effective and favored by Care Partners. However, a minority of telehealth-based interventions allow for health professional engagement and, of these, only a handful provide real-time interaction. Further, Hopwood et al. concluded that, despite the fact that family needs vary across ADRD stages, the interventions reviewed were not targeted to specific stages of dementia.
To address the needs of families living with dementia, the investigators have completed two pilot studies using Internet-based Care Partner interventions. These studies tested the feasibility and consumer acceptability of the evidence-based, STAR-C intervention, the precursor to Tele-STELLA, when delivered via telehealth. Qualitative data revealed the telehealth intervention was acceptable to Care Partners and preferred over a potential in-home intervention. The investigators found that burden was reduced, but depression was not. This may be because the interaction with the Guide formally ended after Session 8, leaving Care Partners with a sense of isolation, as this one commented: "I went through withdrawals… I wanted to call her (the Guide)-who can I turn to?" The prototype interventions did not include meaningful opportunities for Care Partners to interact with each other post-intervention. Care Partners felt their support vanished and did not like "the fact that it was over." Care Partners advised that future interventions should include both one-to-one sessions and one-to-multiple sessions.
Based on the qualitative and quantitative data from the pilot work, Tele-STELLA was designed to address the specific needs of families living with moderate to severe dementia. Tele-STELLA is a multi-component, tailored intervention that begins with one-to-one sessions with each Care Partner and Guide, then links Care Partners to each other in a meaningful way to sustain support post intervention. Tele-STELLA is designed for families living in the later stages of dementia, where behavioral symptoms are more prominent and distressing.
The ultimate goal of this study is to diminish the frequency of behavioral symptoms that persons with dementia experience, and Care Partner reactivity to these symptoms. Based on Kales et al. framework, behavioral symptoms arise from unmet needs, overburdened Care Partners and environmental factors, all within the context of cultural background and beliefs. Behavioral symptoms are bidirectional in that the person with dementia's behaviors affects the Care Partner's behaviors and vice versa. The investigators hypothesize that addressing these factors will reduce behavioral symptom frequency, and, in turn, Care Partner reactivity to them, resulting in reduced Care Partner burden, depression and grief.
Tele-STELLA allows all study activities to be done in Care Partners' homes, using videoconferencing, email and phones. This includes assessments of burden and depression using electronic versions of classic measures. No visits to university sites are needed.
The purpose of this study is to test a revised psychoeducational intervention to help Care Partners for family members with dementia understand and reduce the distressing behaviors that come with progressive dementia. Tele-STELLA (Support via TEchnology: Living and Learning with Advancing Alzheimer's disease and related dementias) is a multicomponent videoconference-based intervention designed to facilitate effective management of behavioral and psychological symptoms common to the later stages of dementia. In the Tele-STELLA intervention, professionals ("Guides") meet with family members ("Care Partners") who care for persons with dementia. Working together, the Care Partners and Guides identify strategies to address upsetting behaviors. The goal of this intervention is to reduce upsetting behaviors and, thus, Care Partner burden.
The specific aims of this study are:
Aim 1. Establish the feasibility and acceptability of Tele-STELLA
Aim 2. Establish the efficacy of Tele-STELLA in reducing the frequency of behavioral and psychological symptoms of dementia (BPSD) and Care Partner reactivity to the symptoms.
H1: Participants who completed the Tele-STELLA intervention will report a significant reduction in the frequency of BPSD and Care Partner reactivity to the BPSD.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Care Recipient Inclusion Criteria:
Care Recipient Exclusion Criteria:
Care Partner Inclusion Criteria:
Care Partner Exclusion Criteria:
Tele-STELLA (Support via TEchnology: Living and Learning with Advancing Alzheimer's disease and related dementias) is a multicomponent videoconference-based intervention designed to facilitate effective management of behavioral and psychological symptoms common to the later stages of dementia.
Time frame: Baseline (1 week pre-Nova); post-Nova (8 weeks); 1-month follow-up (12 weeks). For Constellation: baseline (1 week pre-start); post (8 weeks); 2-month follow-up (16 weeks). Constellation could begin up to 12 months after Nova.
The primary outcome variable, reactivity, will be assessed with the RMBPC, which measures the frequency of care recipient behavioral symptoms and care partner reactions to these behaviors. The RMBPC was chosen because it aligns with our theoretical foundation that assumes burden is a result of care partner reactions to behavioral symptoms.
The RMBPC is a 29-item caregiver report measure, 5-point Likert scale with frequency measuring from 0 (never occurred) to 4 (daily or more often) and reactivity measuring from 0 (not at all) to 4 (extremely) for a total score between 0-116 for each subscale (frequency subscale and reactivity subscale). Higher scores indicate greater behavioral problems.
Time frame: Baseline (1 week pre-Nova); post-Nova (8 weeks); 1-month follow-up (12 weeks). For Constellation: baseline (1 week pre-start); post (8 weeks); 2-month follow-up (16 weeks). Constellation could begin up to 12 months after Nova.
The primary outcome variable, reactivity, will be assessed with the RMBPC, which measures the frequency of care recipient behavioral symptoms and care partner reactions to these behaviors. The RMBPC was chosen because it aligns with our theoretical foundation that assumes burden is a result of care partner reactions to behavioral symptoms.
The RMBPC is a 29-item caregiver report measure, 5-point Likert scale with frequency measuring from 0 (never occurred) to 4 (daily or more often) and reactivity measuring from 0 (not at all) to 4 (extremely) for a total score between 0-116 for each subscale (frequency subscale and reactivity subscale). Higher scores indicate greater behavioral problems.
Time frame: Baseline (1 week pre-Nova); post-Nova (8 weeks); 1-month follow-up (12 weeks). For Constellation: baseline (1 week pre-start); post (8 weeks); 2-month follow-up (16 weeks). Constellation could begin up to 12 months after Nova.
Marwit-Meuser Caregiver Grief Index-Short Form (MM-CGI) is an 18-item caregiver-report measure of pre-death grief. Items are on a 5-point Likert scale and summed for a total score ranging between 18 to 90. Higher scores on this measure indicate greater caregiver grief.
Time frame: Baseline (1 week pre-Nova); post-Nova (8 weeks); 1-month follow-up (12 weeks). For Constellation: baseline (1 week pre-start); post (8 weeks); 2-month follow-up (16 weeks). Constellation could begin up to 12 months after Nova.
The Quality of Life-Alzheimer's Disease (QoL-AD), Care Partner version includes 13 items on a 4-point Likert scale with answers ranging from 1 = poor to 4 = excellent. The total score is the sum of items with a score range between 13-52. Higher scores indicate a better perceived quality of life for the care partner.
Time frame: Baseline (1 week pre-Nova); post-Nova (8 weeks); 1-month follow-up (12 weeks). For Constellation: baseline (1 week pre-start); post (8 weeks); 2-month follow-up (16 weeks). Constellation could begin up to 12 months after Nova.
The 10-item Center for Epidemiologic Studies Depression Scale (CES-D 10) is a self-report measure of depressive symptoms on a 4-point Likert scale with answers ranging from 0-3 (0 = rarely/none to 3 = most/all of the time). Items are summed after reverse scoring for the two positively worded items with a total score range of 0-30. Higher scores indicate greater depressive symptoms.
Time frame: Baseline (first weekly survey at study enrollment, prior to intervention).
Zarit Burden Intervention 4-item (ZBI-4) is a 4-item caregiver-report measure of perceived burden. Items were on a 5-point Likert scale ranging from 0 (never) to 4 (nearly always). The total score was the sum of items with a range of 0-16. Higher scores indicated greater caregiver burden.
Time frame: Baseline (1 week prior to Constellation intervention start)
The Ten Item Personality Inventory (TIPI) is a 10-item Likert scale measure of the Big Five personality traits. Choices range from 1(disagree strongly) to 7 (agree strongly) with reverse scoring on items 2, 4, 6, 8 and 10. Scoring included the average of the two items as follows: extraversion: 1, 6R; agreeableness: 2R, 7; conscientiousness: 3, 8R; emotional stability: 4R, 9; openness to experiences: 5, 10R. Each trait had a score range of 1-7 with higher scores indicating greater standing on each trait dimension.
Time frame: Baseline (at study enrollment) and post-Constellation (8 weeks after Constellation start)
Investigator-developed single-item measure of computer self-efficacy: "I am confident in my ability to use computers." Care partners rated this sentence from 1 (strongly disagree) to 5 (strongly agree), with higher scores indicating greater perceived computer self-efficacy.
Time frame: Baseline (1 week pre-Nova); post-Nova (8 weeks); 1-month follow-up (12 weeks). For Constellation: baseline (1 week pre-start); post (8 weeks); 2-month follow-up (16 weeks). Constellation could begin up to 12 months after Nova.
The Quality of Life-Alzheimer's Disease (QoL-AD), Care Recipient version includes 13 items on a 4-point Likert scale with answers ranging from 1 = poor to 4 = excellent. Care partners reported on this based on how they think their care recipient would respond. The total score is the sum of items with a score range between 13-52. Higher scores indicate a better perceived quality of life for the care recipient.
Oregon Health and Science University
Other
Acronym: Tele-STELLA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04335110
Alzheimer Disease, Behavior
Portland, Oregon, United States
View Trial DetailsNCT05012410
Alzheimer Disease, Arterial Occlusive Diseases
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT05150990
Alzheimer Disease, Behavior
Calabasas, California, United States
View Trial DetailsNCT04271046
Alzheimer Disease, Behavior
Seattle, Washington, United States
View Trial Details